This website uses cookies. By continuing you are agreeing to our privacy policy.

LUNG FORCE
 
  • Share this page:

Investments in Research

Lifesaving Discoveries

Research is the key to new discoveries in lung health and over the past decade, strides have been made in lung cancer treatment and care. Personalized treatment is advancing thanks to biomarker testing and targeted therapies. New methods of early detection with low dose CT scans may increase the chances of survival for individuals at high risk. Still, we know more research is needed to defeat lung cancer.

Our Investment

Funding research is a critical part of the American Lung Association's work. We support a rich array of studies in lung cancer to help develop better treatment options and improve methods of early detection. Since 2014, including our LUNG FORCE investments, we have funded more than $12 million in lung cancer research grants and awards. In FY19 alone, we are providing more than $3 million for lung cancer research funding.

Research Collaborations

In 2017, the American Lung Association partnered with Stand Up to Cancer and the LUNGevity Foundation to announce new lung cancer research awards, bringing together leaders from across disciplines, institutions, and countries to collaborate and move research from bench to bedside to benefit patients more quickly. The Stand Up to Cancer-LUNGevity Foundation-American Lung Association awarded the Lung Cancer Interception Dream Team $5 million and the Lung Cancer Interception Translational Research Team $2 million. These awards marked the American Lung Association's largest single investment in lung cancer research to date.

Lung Cancer Interception Dream Team

The Lung Cancer Interception Dream Team will develop diagnostic tools, such as nasal swabs, blood tests and radiological imaging to confirm whether lung abnormalities found on chest imaging are benign lung disease or lung cancer. To protect against recurrence of disease that has already been successfully treated, new blood tests will help identify patients at the earliest stages of recurrence, enabling timely interventions such as immunotherapy.

  • Leader: Avrum Spira, M.D., professor of medicine, pathology and bioinformatics, and director of the Cancer Center at Boston University-Boston Medical Center.
  • Co-leader: Steven Dubinett, M.D., associate vice chancellor for research at UCLA and director of the lung cancer research program at the Jonsson Comprehensive Cancer Center.

Fostering Cures

This year, a major focus of our research program is to foster projects designed to find cures, prevent and relieve suffering associated with lung cancer. Our 2018-2019 Research Team includes 33 awardees whose studies target lung cancer.

Our Lung Cancer Discovery Award supports meritorious research projects with the potential to:

  • Significantly improve and transform diagnostic and therapeutic paradigms;
  • Foster innovation, use novel approaches; and/or
  • Accelerate progress in lung cancer research that improves patient care and helps save lives.

Meet the Lung Cancer Researchers

  • Mohamed Abazeed, M.D., Ph.D.
    Mapping and Exploiting the Subclonal Architecture of Lung Adenocarcinoma
    American Lung Association researcher Mohamed Abazeed has developed mathematical and experimental models to study the stratification of tumor subclones in topographic space and time.
  • Dennis Adeegbe, Ph.D.
    Boosting Immune Activity in the Fight Against Non-Small Cell Lung Cancer
    American Lung Association researcher Dennis Adeegbe is examining HDAC6 inhibition and Treg-targeting as an immunotherapeutic strategy for non-small cell lung cancer.
  • John Albeck, Ph.D.
    Learning How the Body Repairs Damaged Lung Epithelium
    American Lung Association researcher John Albeck is learning how the body repairs damaged lung epithelium.
  • Joseph Barbi, Ph.D.
    Will Blocking a Nerve Protein Help Stop Lung Tumor Growth?
    American Lung Association researcher Joseph Barbi is exploring how neuritin allows Treg accumulation and function in tumors, and we will determine if blocking neuritin can unleash the immune system to halt lung tumor progression.
  • Lisa Carter-Harris, Ph.D.
    Understanding Low Rates of Referral for Lung Cancer Screening
    American Lung Association researcher Lisa Carter-Harris is studying barriers to discussions and subsequent referral from the clinicians' perspective in order to develop effective interventions for high-risk patients that clinicians will integrate into their practice.
  • Limo Chen, Ph.D.
    Targeting Protein to Improve Immunotherapy for Lung Cancer
    American Lung Association researcher Limo Chen is targeting protein to improve immunotherapy for lung cancer.
  • Simon Cheng, M.D., Ph.D.
    Will Blocking Bmi1 Protein Improve Lung Cancer Immunotherapy?
    American Lung Association researcher Simon Cheng is looking into whether blocking Bmi1 protein will improve lung cancer immunotherapy.
  • Kristina Crothers, M.D.
    Communicating Results of Lung Cancer Screening to Patients
    American Lung Association researcher Kristina Crothers will determine patient factors associated with adherence to follow-up; assess patient understanding and preferences for methods of communicating results of lung cancer screening; and determine whether patients find an individualized report detailing the results of their lung cancer screening is acceptable, decreases distress and helps with understanding.
  • Sharad Goyal, M.D.
    Does Radiation From Heart Procedures Increase Risk of Lung Cancer?
    American Lung Association researcher Sharad Goyal is investigating if radiation during heart procedures causes women to have a greater chance of developing lung cancer compared to men.
  • Pamela Hershberger, Ph.D.
    Reversing Drug Resistance in EGFR Mutant Lung Cancers
    American Lung Association researcher Pamela Hershberger is developing tumor targeted nanoparticles to combat EGFR TKI resistance.
  • Landon Inge, Ph.D.
    Targeting a Cellular Pathway to Treat a Type of Lung Cancer
    American Lung Association researcher Landon Inge has evidence that LKB1-deficient lung cancers rely on a specific pathway to assist in survival. Using novel model systems, we will demonstrate that targeting this pathway will lead to a new approach to treat LKB1-deficient lung cancer.
  • Venkateshwar Keshamouni, Ph.D.
    NK Cell-mediated Immunotherapy against Lung Cancer
    American Lung Association researcher Venkateshwar Keshamouni is defining the role of a protein called CADMI that mediates this tumor cell killing by NK cells and testing strategies to enhance CADM1 expression in tumor cells and also to boost NK cell functions by modulating receptors that recognize CADM1, for the prevention of lung cancer metastasis.
  • Carla Kim, Ph.D.
    Using “Organoid” Model of Lung Cancer to Test Treatment
    American Lung Association researcher Carla Kim is uncovering the earliest vulnerabilities of lung cancer cells and their microenvironment.
  • Ji Yeon Kim, Ph.D.
    Targeting Hexosamine Pathway in an Aggressive Subtype of Lung Cancer
    American Lung Association researcher Ji Yeon Kim is targeting sugar molecule to see if it could lead to new lung cancer treatment.
  • Dan Landau, M.D., Ph.D.
    Using Fragments of DNA in the Blood to Detect Lung Cancer
    American Lung Association researcher Dan Landau developed a novel ultra-sensitive cancer DNA fragment detection method that identifies cancer at very low frequencies and enhances detection in up to two orders of magnitude (a factor of 100). These findings may lead to cancer detection by blood testing.
  • Piro Lito, M.D., Ph.D.
    Treating Lung Cancer with KRAS Mutation
    American Lung Association researcher Piro Lito is building our work describing the mechanism of action of these drugs, we will investigate how cancer cells bypass inhibition of KRAS and then identify optimal combination therapies, in order to maximize the effect of these drugs in patients.
  • Billy Loo, M.D., Ph.D.
    FLASH Radiation Therapy and Immune Response in Lung Cancer
    American Lung Association researcher Billy Loo is studying how a new radiation technology works with the immune system, and test its ability to enhance the impact of immunotherapy on lung cancer.
  • Edwin Ostrin, M.D., Ph.D.
    Enzyme May Play Role in Worsening Immune Function in Lung Cancer
    American Lung Association researcher Edwin Ostrin is investigating the role of KYNU upregulation in lung adenocarcinoma.
  • Griffith Parks, Ph.D.
    Using a Virus to Treat Lung Cancer
    American Lung Association researcher Griffith Parks is using a virus to treat lung cancer.
  • Laura Petrillo, M.D.
    Helping Patients with Lung Cancer Mutations Understand Treatment
    American Lung Association researcher Laura Petrillo will explore patients' understanding of what testing positive for a lung cancer mutation means for their life expectancy, and how doctors convey that information to patients.

    Page Last Updated: January 10, 2019

    About LUNG FORCE

    Donate to LUNG FORCE

    Get Involved

    LUNG FORCE Heroes

    Events Near Me

    Lung Health Barometer

    Media

    Sponsors & Supporters

    Shop LUNG FORCE

    Sign up for updates

    Get the latest news and information on the fight against lung cancer and for lung health.

    Red button with telephone
    Ask An Expert

    Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

    Get help
    Red button of two hand prints
    We need your generous support

    Make a difference by delivering research, education and advocacy to those impacted by lung disease.

    Button of turquoise LUNG FORCE swirl
    What is LUNG FORCE?

    LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

    Get involved
    Join the fight for healthy lungs and healthy air.
    Donate Now.